NLA-EAS joint session: Dyslipidemia Treatment in Light of the New Guidelines
- Lale Tokgözoglu, Turkey
- Antonio Gotto, USA
Targets and goals: The EAS way
Chris Packard, Glasgow, UK
Targets and goals: The NLA way
Carl E. Orringer, Miami, USA
Therapeutic Approaches: The EAS way
Alberico L. Catapano, Milan, Italy
Therapeutic Approaches: The NLA way
Christie Ballantyne, Houston, USA
ESC-EAS joint symposium: A Deep Dive into ESC/EAS Dyslipidemia Guidelines
- Lale Tokgözoglu, Turkey
How to approach a patient with dyslipidemia without apparent CAD (case by Baris Gencer 5 min) What the guideline says
Victoria Delgado, Leiden, The Netherlands
What is the critical evidence behind the guideline
Brian Ference, Cambridge, United Kingdom
How to approach a patient with dyslipidemia with CAD (case by Anna Lebedeva 5 min) What the guideline says
François Mach, Geneva, Switzerland
What is the critical evidence behind the guideline
Alberico L. Catapano, Milan, Italy
IAS-EAS joint symposium: Celebrating the 60th Anniversary of Atherosclerosis
- Lale Tokgözoglu, Turkey
- Raul Santos, Brazil
Is Trimethlyamine-N-Oxide (TMAO) a clinically useful biomarker of increased cardiovascular risk?
Arnold von Eckardstein, Zurich, Switzerland
Distribution of macrophage polarization markers in human atherosclerosis
Menno de Winther, Amsterdam, The Netherlands
